LC two CHM reads for a first in class immunotherapy is totally normal. Why don't you and your team spend the time researching a new OTC to daily short as this one is about to go away. I'm sorry you're losing your sure thing play thing but it's now time to move on.
Market Data 
Markets 
AI
